NCT04740723已完成不适用
A Renal Artery Denervation Feasibility Study of the MetAvention Integrated Radio Frequency Denervation System for the Treatment of Hypertension
Metavention4 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2021年2月6日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 4
- 主要终点
- Rate of Major Adverse Events
研究概览
简要总结
The objective of the study is to evaluate the safety of renal denervation using the iRF System and to understand any potential improvement in hypertension.
详细描述
This study is a prospective, single-arm, multi-center, non-randomized trial to evaluate the initial safety and performance of renal denervation with the iRF system for the treatment of hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Device Feasibility
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 and ≤ 80 years old
- •Office SBP ≥ 140 and < 180 mmHg on a stable dose of antihypertensive medication(s) for at least 30 days
- •Documented daytime systolic ABP ≥ 135 and < 170 mmHg
- •Waist circumference ≥ 102 cm (male) and ≥ 88 cm (female)
排除标准
- •Renal artery anatomy on either side, ineligible for treatment including the following:
- •Main renal artery diameter < 4.0 mm or > 7.0 mm
- •Main renal artery length < 20.0 mm
- •Only one functioning kidney
- •Presence of abnormal kidney tumors
- •Renal artery with aneurysm
- •Pre-existing renal stent or history of renal artery angioplasty
- •Fibromuscular disease of the renal arteries
- •Presence of renal artery stenosis of any origin ≥ 30 %
- •Individual lacks appropriate renal artery anatomy
- •Prior renal denervation procedure
- •Iliac/femoral artery stenosis precluding insertion of the iRF Catheter
- •Evidence of active infection within 7 days of the Index Procedure
- •Type 1 diabetes mellitus
- •Documented history of chronic active inflammatory bowel disorders such as Crohn disease or ulcerative colitis
- •eGFR < 45 mL/min per 1.73 m2
- •Brachial circumference ≥ 42 cm
- •Any history of cerebrovascular event (e.g., stroke, transient ischemic event, and cerebrovascular accident) within 6 months of patient consent
- •Myocardial infarction within 6 months of patient consent
- •Heart failure (New York Heart Association [NYHA] Class III-IV) at time of consent
- •Documented confirmed episode(s) of stable or unstable angina within 6 months of patient consent
- •Documented history of persistent or permanent atrial tachyarrhythmia
- •Chronic oxygen support or mechanical ventilation other than nocturnal respiratory support for sleep apnea
- •Night shift workers
- •Chronic regular use (e.g., daily use) of NSAIDs for 6 months or greater. Aspirin therapy is allowed.
- •Active implantable medical device (e.g., ICD or CRT-D, neuromodulator/spinal stimulator, baroreflex stimulator)
- •Primary pulmonary HTN (> 60 mmHg pulmonary artery or right ventricular systolic pressure)
- •Individual has known pheochromocytoma, Cushing syndrome, primary hyperaldosteronism, coarctation of the aorta, untreated hyperthyroidism, untreated hypothyroidism, or primary hyperparathyroidism. (Note: Treated hyperthyroidism and treated hypothyroidism are permissible.)
- •Documented contraindication or allergy to contrast medium not amenable to treatment
- •Limited life expectancy of < 1 year at the discretion of the investigator
- •Any known, unresolved history of drug use or alcohol dependency, lacks the ability to comprehend or follow instructions, or for any reason in the opinion of the investigator, would be unlikely or unable to comply with study protocol requirements or whose participation may result in data analysis confounders (e.g., night shift workers)
- •Pregnant, nursing, or planning to become pregnant (documented negative pregnancy test result required documented within a maximum of 7 days before procedure for all women of childbearing potential)
- •Concurrent enrollment in any other investigational drug or device trial (participation in noninterventional registries is acceptable)
结局指标
主要结局
Rate of Major Adverse Events
时间窗: Index Procedure through 30 days
Incidence of the following Major Adverse Events (MAEs) * Death (all-cause) * New onset end stage renal disease * Significant embolic events resulting in end-organ damage * Renal artery perforation or dissection requiring intervention * Hospital admission for hypertensive crisis not related to confirmed non-adherence with medications or protocol * New renal stenosis \> 70 %
次要结局
- Effects on renal function assessed with glomerular filtration rate(Time Frame: 30, 90, 180 and 365 days)
- Change in Systolic/Diastolic Blood Pressure - Ambulatory Blood Pressure Monitoring(Time Frame: 90, 180 and 365 days)
- Change in Systolic/Diastolic Blood Pressure - Average Automated Office Blood Pressure(Time Frame: 30, 90, 180 and 365 days)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Renal Denervation Using Externally Focused Therapeutic UltrasoundHypertensionNCT01926951Kona Medical Inc.27
Unknown
不适用
Renal Denervation With Sterile Irrigated Deflectable Ablation Catheter Used in Renal Artery in Primary HypertensionPrimary HypertensionNCT03511313Synaptic Medical Corporation264
Unknown
1 期
Influence of Catheter-based Renal Denervation in Diseases With Increased Sympathetic ActivityHeart Rhythm DisordersHypertensionHeart FailureDiabetesChronic Kidney DiseaseNCT01888315University Hospital, Saarland1,000
撤回
不适用
The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating PainAutosomal Dominant Polycystic Kidney DiseaseNCT02746419University of Chicago
招募中
不适用
DENEX Renal Denervation in Patients With Hypertension on no Antihypertensive MedicationsVascular DiseasesCardiovascular DiseasesHypertensionNCT04535050Kalos Medical100